WASHINGTON, Feb. 12, 2013 (GLOBE NEWSWIRE) -- CNS Response, Inc. (OTCBB:CNSO) today announced it has received official notification from Walter Reed National Military Medical Center Institutional Review Board that it will begin using its new technology, PEER Interactive, in a multi-site clinical trial. PEER Interactive is an emerging technology designed to support physicians in identifying the best treatments for certain psychiatric disorders.
During the clinical trial at Walter Reed National Military Medical Center and Fort Belvoir Community Hospital, military physicians will treat 2,000 volunteer study patients with a primary diagnosis of Depression. The patients may also have comorbid disorders such as post-traumatic stress disorder (PTSD), mild traumatic brain injury (mTBI), and other psychiatric disorders. Additional sites, including at least one region of the Veterans Administration, are anticipated during 2013. The Henry M. Jackson Foundation has joined CNS Response as a research partner, providing clinical trial support in all locations.
The study – a prospective, randomized, multi-site, double blind study of the utility of PEER Interactive in improving medication outcomes in mental health - will commence during February 2013 and enroll patients throughout the year. The Company anticipates analysis of interim data by the end of 2013.
LTC (P) Brett Schneider, M.D., Chief of Psychiatry at Walter Reed - Principal Investigator for the Study - stated, "We are absolutely committed to the prompt evaluation and demonstration of more effective technologies in the treatment of psychiatric disorders. We are enthusiastic about the promise of the PEER technology and we look forward to leading this important study."
George Carpenter, CEO, CNS Response added, "With PEER, doctors have a tool that can significantly improve outcomes for the individual. This project represents one of the largest recent trials in clinical psychiatry, and will add to the cumulative evidence of over 75 published EEG-medication response studies. We look forward to working with military leadership to demonstrate the utility of this approach."
CNS Response's new technology, PEER Interactive, is a cloud-based decision support tool which takes results of a standard electroencephalogram (EEG), which records a patient's brain function much like an electrocardiogram (EKG) records heart function. Developed by physicians as a quality assurance tool, PEER Interactive enables medical professionals to compare and learn which psychiatric medications have been more effective, and which have been less effective when used by their fellow physicians treating patients with similar EEG findings.
About CNS Response
CNS Response is a clinical decision support company with a commercial neurometric platform that helps physicians predict drug response for treatment of psychiatric disorders, including depression, anxiety, bipolar disorder and post-traumatic stress disorder. Although treatment has doubled in the last 20 years, it is estimated that over 17 million Americans have failed two or more medication therapies for their mental disorder. The Company's Psychiatric EEG Evaluation Registry (PEER) is a new registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients, referenced to objective neurophysiology data obtained through an EEG. Based on the company's original physician-developed database, there are now over 35,000 outcomes in the PEER registry. The objective of PEER Interactive is to avoid trial and error pharmacotherapy, which is the dominant approach for treatment resistant patients.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.cnsresponse.com. Medical professionals interested in learning more can contact CNS Response at PEERinfo@cnsresponse.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
Except for the historical information contained herein, the matters discussed above, particularly related to the proposed study to be conducted by CNS, the possible outcomes and the potential benefits of its product, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein. CNS has not entered into a definitive agreement with WRNMC relating to the conduct of a trial. Walter Reed may not proceed with a trial with CNS or, once it has started, may terminate the trial at any time. Furthermore, CNS cannot predict the results or the success of any trial, if and once completed.
CONTACT: Investor Relations: Marty Tullio, Managing Partner McCloud Communications, LLC 949.553.9748 (office); 949.632.1900 (cell) email@example.com Media Relations: Capitol Media Partners 310.742.6936 (office) firstname.lastname@example.orgSource:CNS Response